

Additional file 3: Table S3. Specificity of T-activated EBV- and HCMV-proteins

Antigen	Donor	EBV-/CMV-serostatus	SFC ^a /2x10 ⁵ PBMC	Specificity
EBV-BZLF1	S01	negative	0	100 %
EBV-BZLF1	S02	negative	0	
EBV-BZLF1	S03	negative	0	
EBV-BZLF1	S04	negative	0	
EBV-BZLF1	S05	negative	0	
EBV-BZLF1	S06	negative	0	
EBV-BZLF1	S07	negative	0	
EBV-EBNA3A	S01	negative	0	86 %
EBV-EBNA3A	S02	negative	0	
EBV-EBNA3A	S03	negative	0	
EBV-EBNA3A	S04	negative	15	
EBV-EBNA3A	S05	negative	0	
EBV-EBNA3A	S06	negative	0	
EBV-EBNA3A	S07	negative	0	
HCMV-IE1	S01	negative	0	100 %
HCMV-IE1	S02	negative	0	
HCMV-IE1	S03	negative	0	
HCMV-IE1	S04	negative	0	
HCMV-IE1	S05	negative	0	
HCMV-IE1	S06	negative	0	
HCMV-IE1	S07	negative	0	
HCMV-pp65	S01	negative	0	100 %
HCMV-pp65	S02	negative	0	
HCMV-pp65	S03	negative	0	
HCMV-pp65	S04	negative	0	
HCMV-pp65	S05	negative	0	
HCMV-pp65	S06	negative	0	
HCMV-pp65	S07	negative	0	
EBV-BZLF1	S08	positive	29	
EBV-BZLF1	S09	positive	148	
EBV-BZLF1	S10	positive	409	
EBV-EBNA3A	S08	positive	40	
EBV-EBNA3A	S09	positive	126	
EBV-EBNA3A	S10	positive	452	
HCMV-IE1	S11	positive	12	
HCMV-IE1	S12	positive	26	
HCMV-IE1	S13	positive	19	
HCMV-pp65	S11	positive	128	
HCMV-pp65	S12	positive	572	
HCMV-pp65	S13	positive	235	

^a Values are the mean number of antigen-specific IFN- γ SFC/2x10⁵ PBMC (stimulated with 10 μ g/ml EBV-BZLF1, 15 μ g/ml EBV-EBNA3A, 3 μ g/ml HCMV-pp65, and 15.6 μ g/ml HCMV-IE1 T-activated proteins, respectively). Results illustrate examination of specificity of T-cell responses against EBV-BZLF1, -EBNA3A, HCMV-IE1, and -pp65 TP in a cohort of EBV- and HCMV-seronegative donors, where an absence of a recall response to EBV- and HCMV-derived antigens is expected. Additionally, numbers of SFC of six donors with confirmed positive EBV- and HCMV-serostatus are listed.